Abstract
Sebetralstat is an investigational oral plasma kallikrein inhibitor for the on-demand treatment of HAE attacks. This trial compares PK characteristics, safety, and tolerability of sebetralstat administered as orally disintegrating tablets (ODT) and film coated tablets (FCT) in healthy volunteers. ODT may improve ease of treatment administration in pediatric and adult HAE populations.
Full Text 
Sign-in/Register to access full text options
Sign-in/Register to access full text options 
Published version (
Free)
Free) 
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Schedule a call
